EMA filing acceptance and validation for spesolimab
Boehringer Ingelheim announces European Medicines Agency ’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news